贵州医科大学学报2024,Vol.49Issue(9) :1385-1391.DOI:10.19367/j.cnki.2096-8388.2024.09.020

消疣汤对宫颈HR-HPV持续感染患者疗效及对宫颈癌Hela细胞上皮间充质转化的影响

Therapeutic effect of Xiaoyou decoction on patients with cervical HR-HPV persistent infection and its effect on epithelial-mesenchymal transition in cervical cancer HeLa cells

门昊 艾雯霞 刘丽
贵州医科大学学报2024,Vol.49Issue(9) :1385-1391.DOI:10.19367/j.cnki.2096-8388.2024.09.020

消疣汤对宫颈HR-HPV持续感染患者疗效及对宫颈癌Hela细胞上皮间充质转化的影响

Therapeutic effect of Xiaoyou decoction on patients with cervical HR-HPV persistent infection and its effect on epithelial-mesenchymal transition in cervical cancer HeLa cells

门昊 1艾雯霞 1刘丽2
扫码查看

作者信息

  • 1. 黑龙江中医药大学第一临床医院,黑龙江哈尔滨 150000
  • 2. 黑龙江中医药大学第一附属医院宫腔镜室,黑龙江哈尔滨 150000
  • 折叠

摘要

目的 探究消疣汤对宫颈HR-HPV持续感染患者的疗效及对宫颈癌Hela细胞上皮间充质转化(EMT)影响.方法 收集高危型人乳头瘤病毒(HR-HPV)持续感染且病理分级为CIN Ⅰ级的患者114例随机均分为干扰素组和消疣汤组,干扰素组应用重组人干扰素α-2b凝胶、消疣汤组在干扰素组的基础上给予消疣汤治疗,与治疗3个月时评价两组患者中医症候积分和临床疗效;将宫颈癌Hela细胞随机分为空白对照组(Control组),消疣汤低剂量组(XYD-L组,1 g/L)、中剂量组(XYD-M组,2 g/L)及高剂量组(XYD-H组,4 g/L),于24、48及72 h时,采用CCK-8法Hela细胞增殖能力、Transwell法检测侵袭能力、蛋白质印迹法检测细胞中E-Cadherin、N-Cadherin、Vimentin表达.结果 与Control组相比,XYD-L组、XYD-M组和XYD-H组Hela细胞增殖能力、侵袭数目及细胞中N-Cadherin、Vimentin蛋白表达明显降低,细胞中E-Cadherin蛋白表达均明显增加(P<0.05);XYD-H组宫颈癌细胞增殖能力、侵袭数目及细胞中N-Cadherin、Vimentin蛋白表达明显低于XYD-L组、XYD-M组,细胞中E-Cadherin蛋白表达明显高于XYD-L组、XYD-M组(P<0.05);干扰素组HR-HPV持续感染患者治疗3个月时的临床疗效总有效率为78.95%、消疣汤组临床疗效总有效率(94.74%),P<0.05;和治疗前相比,治疗后两组患者中医症候积分明显降低(P<0.05);与治疗后干扰素组相比,消疣汤组患者中医症候积分明显降低(P<0.05).结论 消疣汤可明显改善宫颈HR-HPV持续感染患者临床症状,其机制可能与消疣汤影响宫颈癌细胞EMT及细胞的增殖和侵袭有关.

Abstract

Objective To investigate therapeutic effect of Xiaoyou decoction on patients with cervical HR-HPV persistent infection and its effect on epithelial-mesenchymal transition(EMT)in cervical cancer Hela cells.Methods A total of 114 patients with HR-HPV persistent infection and pathological grade CIN Ⅰ were randomly divided into interferon group and Xiaoyou decoction group.Interferon group was treated with recombinant human interferon α-2b gel,and Xiaoyou decoction(XYD)group was treated with XYD on the basis of interferon group.Traditional Chinese medicine(TCM)syndrome score and clinical efficacy were evaluated in two groups of the patients at 3 months of treatment.Cervical cancer Hela cells were randomly divided into a blank control group(Control group),a low-dose XYD group(XYD-L group,1 g/L),a medium dose XYD group(XYD-M group,2 g/L),and a high-dose XYD group(XYD-H group,4 g/L).At 24,48,and 72 hours,CCK-8 assay was used to assess Hela cell proliferation capacity,and Transwell assay was applied to examine cell invasion capacity.Western blot was applied to detect the expressions of E-Cadherin,N-Cadherin,and Vimentin.Results When compared to control group,Hela cell proliferation capacity,invaded cell number and protein expression of N-Cadherin and Vimentin were significantly reduced in XYD-L,XYD-M,and XYD-H groups,while E-Cadherin protein expression was significantly increased(P<0.05).Cervical cancer cell proliferation capacity,invaded cell number and protein expression of N-Cadherin and Vimentin were significantly lower in XYD-H group than those in XYD-L and XYD-M groups,while E-cadherin protein expression was significantly higher than that in XYD-L and XYD-M groups(P<0.05).The total effective rate of clinical efficacy in patients with HR-HPV persistent infection was 78.95%in interferon group at 3 months of treatment,while the total effective rate of clinical efficacy in Xiaoyu decoction group was 94.74%(P<0.05).When compared to before treatment,TCM symptom scores of both groups of patients were significantly decreased after treatment(P<0.05).When compared to interferon group after treatment,TCM syndrome score of patients in Xiaoyu decoction group was significantly reduced(P<0.05).Conclusion Xiaoyou decoction can significantly improve clinical symptoms in patients with cervical HR-HPV persistent infection.Its mechanism may be related to the effects of the Xiaoyou decoction on EMT,proliferation and invasion of cervical cancer cells.

关键词

消疣汤/宫颈HR-HPV持续感染/宫颈肿瘤/侵袭/上皮间充质转化

Key words

xiaoyou decoction/cervical HR-HPV persistent infection/cervical cancer/invasion/epithelial-mesenchymal transition

引用本文复制引用

基金项目

教育部春晖计划合作科研项目(HLJ2019032)

黑龙江省中医药科研项目(GY2022-26)

出版年

2024
贵州医科大学学报
贵阳医学院

贵州医科大学学报

CSTPCD
影响因子:0.827
ISSN:2096-8388
段落导航相关论文